Cost control under the DRG system.

M A Helmi; S Burton

Home/Archive/PubMed

PubMed · 10312525

Cost control under the DRG system.

M A Helmi·S Burton

View original source ↗Export metadata ↓

Abstract

The change in the method of reimbursing hospitals from a retrospective to a prospective payment system known as diagnosis-related group (DRG) caused hospitals to increase control over their costs. This article details a system for cost control that gives timely feedback on the hospital's reimbursement position and allows the hospital to recognize areas that require their attention for proper control over costs. Three variances are discussed: controllable variance, standard variance, and total variance. The system was tested on a hospital found to have enough information for this purpose. The results of this application indicate that the system is as feasible in the hospital industry as it is in other industries.

Explore related subjects

Cost Control Diagnosis-Related Groups Efficiency Financial Management Financial Management, Hospital Models, Theoretical Prospective Payment System Statistics as Topic United States Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

M A Helmi, S Burton. 1988. Cost control under the DRG system.. https://pubmed.ncbi.nlm.nih.gov/10312525/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Cancer care, money, and the value of life: whose justice? Which rationality?

Cost-containment in oncology is a moral issue. While economists use the word "rationing" to describe all limitations on resource utilization that result from human choice, the ordinary language distinction between allocation and rationing is morally meaningful and can help oncologists to determine their proper moral role in cost-containment. It is argued that oncologists should not be required to ration at the bedside, nor should they be given financial incentives to practice frugally, nor should they be subjected to a variety of bureaucratic mechanisms to control costs indirectly. In addition, it is argued that the fact that treatments have a price does not logically imply that patients have a price. Cost-effectiveness analysis is often suggested as a means of deciding how best to allocate resources, but some of its many ethical limitations are discussed. The alternative is an open, public, participatory process about how to ration care, abandoning the formulaic pretenses of cost-effectiveness analysis, but with a commitment to reason, good will, and common sense. Oncologists would then be free to advocate for their patients within the constraints imposed by this public process.

Cost Control↗

PubMed2007

How should we pay the piper when he's calling the tune? On the long-term affordability of cancer care in the United States.

Explore the source record for details and available documents.

Cost Control↗

PubMed2007

Documentation of pharmacists' interventions in an emergency department and associated cost avoidance.

PURPOSE: An analysis was conducted of pharmacist interventions and resuscitation experiences, including pharmacist participation in a hospital emergency department (ED), and the potential cost avoidance associated with the interventions made by the pharmacists. METHODS: All pharmacists working in the ED prospectively documented the pharmacist interventions that were accepted by physicians and nursing staff and entered into a spreadsheet on a weekly basis, between September 1, 2003, and December 31, 2003. Intervention categories included the provision of drug information; recommendations for dosage adjustment, formulary interchange, initiation of medications, alternative drug therapy, discontinuation of drug therapy, changes in medication therapy due to allergy notification, drug therapy duplication prevention, or changes in the route of drug administration; questions from nursing staff; order clarifications; drug compatibility issues; patient information; toxicology; and drug interaction identification. Intervention data were analyzed and the likelihood of harm was scored; interventions were classified and analyzed by calculating average cost, probability of harm, and potential cost avoidance. RESULTS: During the study, 2150 pharmacist interventions were documented. Pharmacists participated in the care of 1042 patients triaged to the resuscitation area of the ED. Cost avoidance during the study was determined to be 1,029,776 dollars. CONCLUSION: The most commonly documented interventions made by pharmacists involved in the care of patients visiting the ED included provision of drug information, dosage adjustment recommendations, responses to questions from nursing staff, formulary interchanges, and suggestions regarding initiation of drug therapy. The potential cost avoidance attributable to the pharmacist interventions during the study period was over 1 million dollars.

Cost Control↗